Logan Reed
The COVID-19 pandemic has led to the development and distribution of several vaccines to help prevent the spread of the virus. The U.S. Food and Drug Administration (FDA) approved the first COVID-19 vaccine, the Pfizer-BioNTech vaccine, in 2021, and it has since been marketed as Comirnaty. The Moderna vaccine was approved in January 2022, and both vaccines target the KP.2 strain. The FDA has also authorized the use of these vaccines for children over 6 months old and for adolescents between 12 and 15 years of age under emergency use authorization (EUA). EUA allows the FDA to review and authorize products quickly during public health emergencies, and it is different from full FDA approval, which requires a longer evaluation period.
| Characteristics | Values |
|---|---|
| First FDA-approved COVID-19 vaccine | Pfizer-BioNTech COVID-19 Vaccine, now marketed as Comirnaty |
| First approval date | Summer of 2021 |
| Age group | Individuals 16 years of age and older |
| Second FDA-approved COVID-19 vaccine | Moderna vaccine |
| Second approval date | January 2022 |
| Age group | Individuals 18 years of age and older |
| Third FDA-approved COVID-19 vaccine | Johnson & Johnson vaccine |
| Age group | Individuals older than 6 months |
Explore related products
What You'll Learn
The Pfizer-BioNTech COVID-19 vaccine is FDA-approved
The FDA's approval process for vaccines involves a thorough review of data and information provided by the manufacturer in a biologics license application (BLA). The BLA for Comirnaty was based on extensive preclinical and clinical data, manufacturing process details, vaccine testing results, and inspections of production sites. The FDA conducts its own analyses to ensure the vaccine meets its stringent standards for approval.
It's important to distinguish between FDA approval and Emergency Use Authorization (EUA). While the Pfizer-BioNTech vaccine has full FDA approval for individuals 16 and older, it is also available under EUA for individuals aged 12 to 15. EUA allows the use of vaccines during emergencies when there are no adequate approved alternatives. The EUA for the Pfizer-BioNTech vaccine was expanded to include adolescents based on available safety data and ongoing clinical trials.
The FDA has also issued an EUA for a second COVID-19 vaccine, the Moderna COVID-19 Vaccine, for individuals 18 years of age and older. This vaccine is undergoing additional safety monitoring through a pharmacovigilance plan to ensure any potential concerns are promptly identified and addressed. The availability of multiple vaccines, including the fully approved Pfizer-BioNTech option, represents crucial steps forward in protecting public health and ending the pandemic.
Vaccine Side Effects: Blood Vessel Trauma
You may want to see also
Explore related products
$2.97 $24.95
Moderna COVID-19 vaccine approved in January 2022
The Food and Drug Administration (FDA) approved the first COVID-19 vaccine, the Pfizer-BioNTech COVID-19 vaccine, which is now marketed as Comirnaty. This vaccine is approved for the prevention of COVID-19 disease in individuals 16 years of age and older. The FDA has also issued an emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine for adolescents aged 12 to 15.
The FDA has also issued an EUA for the Moderna COVID-19 vaccine, which was authorized for individuals 18 years of age and older. On January 31, 2022, the FDA approved a Biologics License Application (BLA) for the use of the Moderna COVID-19 vaccine in individuals aged 18 years and older. The Advisory Committee on Immunization Practices (ACIP) issued a standard recommendation for the use of this vaccine on February 4, 2022.
The EUA is different from FDA approval, as a vaccine available under EUA is not approved. The FDA evaluates the available evidence to determine the effectiveness and benefit-risk assessment of a vaccine before issuing an EUA. The Moderna COVID-19 vaccine was granted EUA in December 2020, and approximately 204 million doses were administered in the United States as a primary series of two intramuscular doses from December 19, 2020, to January 30, 2022.
The Moderna COVID-19 vaccine is a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. The benefits of the vaccine in preventing infection, hospitalization, and death outweigh the associated risks.
Hepatitis A Vaccine: Understanding the Type and Its Benefits
You may want to see also
Explore related products
EUA: Emergency Use Authorization
The Food and Drug Administration (FDA) has approved the Pfizer-BioNTech COVID-19 vaccine, which is now marketed as Comirnaty, for individuals 16 years of age and older. The Pfizer-BioNTech vaccine was the first to receive FDA approval. The FDA has also approved the Moderna vaccine as of January 2022.
The FDA has also issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine. EUA allows the use of unapproved medical products or unapproved uses of approved medical products in an emergency when there are no adequate, approved, and available alternatives. EUA is different from FDA approval (licensure) of a vaccine, as a vaccine available under EUA is not approved. To grant an EUA, the FDA must determine that a vaccine's benefits outweigh its risks and that it meets the effectiveness standard. The EUA will be effective until the declaration that circumstances justify its authorization is terminated.
The EUA for the Pfizer-BioNTech vaccine was expanded to include adolescents 12 through 15 years of age. The EUA for the Moderna vaccine allows it to be distributed in the US for use in individuals 18 years of age and older. The FDA has also authorized the Pfizer-BioNTech and Moderna vaccines for use in children older than 6 months.
Yellow Fever Vaccine: Risky for Seniors
You may want to see also
Explore related products
FDA approval standards for vaccines
The U.S. Food and Drug Administration (FDA) has approved the first COVID-19 vaccine, known as the Pfizer-BioNTech COVID-19 Vaccine, now marketed as Comirnaty. The vaccine is approved for the prevention of COVID-19 disease in individuals 16 years of age and older. The Pfizer-BioNTech COVID-19 Vaccine has also been authorized by the FDA for emergency use in adolescents 12 to 15 years of age.
The FDA has a rigorous process for reviewing the quality, safety, and effectiveness of vaccines before approval. The FDA's Center for Biologics Evaluation and Research (CBER) ensures that the FDA's rigorous scientific and regulatory processes are followed during vaccine development. Vaccine manufacturers are required to submit data supporting manufacturing processes, facilities, product characterization, and lot-to-lot consistency. The FDA evaluates the data and information included in the manufacturer's submission of a biologics license application (BLA). The BLA provides comprehensive information, including preclinical and clinical data, details of the manufacturing process, vaccine testing results, and inspections of the manufacturing sites.
The FDA conducts its own analyses of the information in the BLA to ensure the vaccine meets the required standards for safety and effectiveness. The FDA also expects manufacturers to continue clinical trials and pursue approval even after a vaccine has been authorized for emergency use. Post-authorization vaccine safety monitoring is a critical aspect of the process, with multiple systems in place to rapidly detect any possible vaccine safety concerns.
The FDA's approval of the Pfizer-BioNTech COVID-19 Vaccine is a significant milestone in the battle against the COVID-19 pandemic. The vaccine has undergone the FDA's rigorous evaluation process, providing confidence in its safety and effectiveness.
Understanding the Tetanus Vaccine's Abbreviation
You may want to see also
Explore related products
COVID-19 vaccines are safe and effective
The COVID-19 vaccine is very effective at preventing serious illness, hospitalization, and death. It teaches the immune system to recognize and fight the virus, and the 2024-25 vaccine is updated to better protect against newer variants. Studies show that COVID-19 vaccines are most effective during the first three months after vaccination. While natural immunity to the virus weakens over time, vaccine-acquired immunity is safer and more durable.
The FDA and CDC are committed to monitoring the safety of COVID-19 vaccines. The Vaccine Adverse Event Reporting System (VAERS) is an early warning system co-managed by the FDA and CDC that monitors for potential vaccine safety problems. Healthcare providers are required to report specific adverse events following vaccination, and the CDC also uses V-safe to monitor how individuals feel after vaccination. Anaphylaxis, myocarditis or pericarditis, and Guillain-Barré syndrome (GBS) are identified as rare but serious adverse events following COVID-19 vaccination.
COVID-19 vaccines have undergone and continue to undergo intensive safety analysis and monitoring to ensure their safety and effectiveness. Millions of people have received the vaccines, and the CDC and FDA continue to monitor their safety and effectiveness, including rare adverse events. The COVID-19 vaccines are safe and effective at preventing serious illness, hospitalization, and death, and they are continuously updated to protect against new variants.
Pneumonia Vaccine: How Often for Protection?
You may want to see also
Frequently asked questions
Yes, the Pfizer-BioNTech COVID-19 vaccine, now marketed as Comirnaty, was approved by the FDA in 2021 for the prevention of COVID-19 disease in individuals 16 years of age and older. The Moderna vaccine was approved in January 2022.
EUA is granted when the FDA determines that a vaccine can effectively prevent infection or disease and that its benefits outweigh potential risks. A vaccine available under an EUA is not approved by the FDA.
The FDA-approved Pfizer-BioNTech vaccine, Comirnaty, is recommended for individuals 16 years of age and older. The Moderna vaccine is recommended for individuals 18 years of age and older.
Yes, COVID-19 vaccines approved by the FDA are safe and recommended for pregnant or lactating individuals, as well as those intending to become pregnant. Pregnant women are at a greater risk for severe COVID-19, which can lead to a higher risk of preterm birth, stillbirth, and other complications.
